EP3843761A4 - CHIMERIC ONCOLYTIC HERPESVIRUS STIMULATING AN ANTI-TUMORROW IMMUNE RESPONSE - Google Patents

CHIMERIC ONCOLYTIC HERPESVIRUS STIMULATING AN ANTI-TUMORROW IMMUNE RESPONSE Download PDF

Info

Publication number
EP3843761A4
EP3843761A4 EP19855584.9A EP19855584A EP3843761A4 EP 3843761 A4 EP3843761 A4 EP 3843761A4 EP 19855584 A EP19855584 A EP 19855584A EP 3843761 A4 EP3843761 A4 EP 3843761A4
Authority
EP
European Patent Office
Prior art keywords
stimulate
immune response
antitumor immune
chimeric oncolytic
oncolytic herpesvirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19855584.9A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3843761A1 (en
Inventor
Kevin A. Cassady
Justin C. ROTH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Institute at Nationwide Childrens Hospital
Original Assignee
Research Institute at Nationwide Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Institute at Nationwide Childrens Hospital filed Critical Research Institute at Nationwide Childrens Hospital
Publication of EP3843761A1 publication Critical patent/EP3843761A1/en
Publication of EP3843761A4 publication Critical patent/EP3843761A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP19855584.9A 2018-08-31 2019-08-30 CHIMERIC ONCOLYTIC HERPESVIRUS STIMULATING AN ANTI-TUMORROW IMMUNE RESPONSE Pending EP3843761A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862725809P 2018-08-31 2018-08-31
PCT/US2019/049047 WO2020047398A1 (en) 2018-08-31 2019-08-30 Chimeric oncolytic herpesvirus that stimulate an antitumor immune response

Publications (2)

Publication Number Publication Date
EP3843761A1 EP3843761A1 (en) 2021-07-07
EP3843761A4 true EP3843761A4 (en) 2022-06-08

Family

ID=69643794

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19855584.9A Pending EP3843761A4 (en) 2018-08-31 2019-08-30 CHIMERIC ONCOLYTIC HERPESVIRUS STIMULATING AN ANTI-TUMORROW IMMUNE RESPONSE

Country Status (10)

Country Link
EP (1) EP3843761A4 (he)
JP (1) JP2021534786A (he)
KR (1) KR20210053923A (he)
CN (1) CN113396217A (he)
AU (1) AU2019333181A1 (he)
BR (1) BR112021003807A8 (he)
CA (1) CA3110406A1 (he)
IL (1) IL281085A (he)
SG (1) SG11202101829UA (he)
WO (1) WO2020047398A1 (he)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023096996A2 (en) 2021-11-24 2023-06-01 Research Institute At Nationwide Children's Hospital Chimeric hsv expressing hil21 to boost anti-tumor immune activity
WO2023235377A1 (en) * 2022-05-31 2023-12-07 The Research Institute At Nationwide Children's Hospital Il-27 expressing oncolytic viruses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
WO2007005876A2 (en) * 2005-07-01 2007-01-11 The Uab Research Foundation Chimeric herpes viruses and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GHONIME MOHAMMED G ET AL: "Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 9, no. 10, 26 August 2021 (2021-08-26), pages e002939, XP055915209, Retrieved from the Internet <URL:https://jitc.bmj.com/content/jitc/9/10/e002939.full.pdf?with-ds=yes> DOI: 10.1136/jitc-2021-002939 *
GHONIME MOHAMMED G. ET AL: "Chimeric HCMV/HSV-1 and [Delta][gamma]134.5 oncolytic herpes simplex virus elicit immune mediated antigliomal effect and antitumor memory", TRANSLATIONAL ONCOLOGY, vol. 11, no. 1, 1 February 2018 (2018-02-01), United States, pages 86 - 93, XP055915040, ISSN: 1936-5233, DOI: 10.1016/j.tranon.2017.10.005 *
See also references of WO2020047398A1 *

Also Published As

Publication number Publication date
SG11202101829UA (en) 2021-03-30
KR20210053923A (ko) 2021-05-12
IL281085A (he) 2021-04-29
CA3110406A1 (en) 2020-03-05
AU2019333181A1 (en) 2021-03-18
BR112021003807A8 (pt) 2022-04-19
WO2020047398A9 (en) 2020-04-30
JP2021534786A (ja) 2021-12-16
WO2020047398A1 (en) 2020-03-05
BR112021003807A2 (pt) 2021-05-18
CN113396217A (zh) 2021-09-14
EP3843761A1 (en) 2021-07-07

Similar Documents

Publication Publication Date Title
EP3596118A4 (en) PROCESSES FOR MODULATING AN IMMUNE RESPONSE
EP3405190A4 (en) METHOD FOR TRIGGERING AN IMMUNE REACTION
EP3289083A4 (en) Nucleoside-modified rna for inducing an adaptive immune response
EP3697592A4 (en) 3D PRINTER
EP3283110A4 (en) ANTIBODIES DIRECTED AGAINST THE INTERLEUKIN 36 RECEPTOR (IL-36R)
EP3756996A4 (en) FLYING OBJECT
EP3842529A4 (en) EXOSOME-BASED ANTITUMORS
EP3529914A4 (en) UPLINK REFERENCE SIGNAL
EP3422867A4 (en) MICROBES WITH DIRECT POWER SUPPLY
EP3596610A4 (en) COOKING SYSTEM
EP3585409A4 (en) CHEMERICAL PROTEINS BASED ON CSF1R
EP3946448A4 (en) SEMI-SYNTHETIC BIOPOLYMERS FOR USE IN IMMUNE SYSTEM STIMULATION
EP4003535A4 (en) PREBIOTIC-INDUCED TUMOR IMMUNITY
EP3664576A4 (en) HEATER
IL281085A (he) וירוס הרפס אונקוליטי כימרי המעורר תגובה חיסונית של אנטי-שאת
EP3752163A4 (en) PROMOTING IMMUNE RESPONSES
EP3612371A4 (en) 3D PRINTER AND CONSTRUCTION MODULE
EP3904773A4 (en) HEATING SYSTEM
EP3585410A4 (en) VSIG8-BASED CHIMERIC PROTEINS
EP3894182A4 (en) 3D PRINTER
EP3779285A4 (en) HEATING SYSTEM
EP3814110A4 (en) 3D PRINT ORDER
EP3522721A4 (en) OVEN SYSTEM
EP3416727A4 (en) IMPROVED INTERFERON THERAPY
EP3380197A4 (en) COMPOSITIONS AND METHOD FOR MODULATING AN IMMUNE REACTION

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20210308

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20220506

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/02 20060101ALI20220429BHEP

Ipc: A61P 35/04 20060101ALI20220429BHEP

Ipc: C12N 15/00 20060101ALI20220429BHEP

Ipc: C12N 7/01 20060101ALI20220429BHEP

Ipc: A61K 35/76 20150101AFI20220429BHEP